Dumont J M, Maignan M F, Janin B, Herbage D, Perrissoud D
J Hepatol. 1986;3(2):260-8. doi: 10.1016/s0168-8278(86)80036-8.
The effect of malotilate, a new drug proposed for the treatment of chronic liver diseases, was studied in carbon tetrachloride (CCl4)-induced chronic liver injury in the rat. Treatment with CCl4 (0.5 ml/kg twice per week, intraperitoneally for 6 or 9 weeks) led to marked necrosis, steatosis and fibrosis, as shown by both biochemical and histological examinations, and a significant decrease of the bromosulfophtaleine (BSP) clearance test. Malotilate (50 mg/kg p.o., 5 days per week given simultaneously with CCl4 for 6 weeks), suppressed the increase of plasma aminotransferase activity and decreased significantly the accumulation of lipid and collagen in the liver; histology confirmed this protective effect of malotilate. The BSP clearance test returned to normal values and the rise in hepatic collagen synthesis activity in the malotilate-treated and intoxicated rats was reduced as compared with intoxicated control rats. The same effect was found when malotilate (100 mg/kg, p.o., 5 days per week), was given for 3 weeks to rats already intoxicated during the 6 previous weeks. Malotilate was able to prevent the increase of hepatic alterations that appeared during the last 3 weeks of CCl4 intoxication. These results show clearly that malotilate can markedly reduce the hepatic disorders induced by a chronic CCl4 intoxication in the rat.
研究了一种用于治疗慢性肝病的新药马洛替酯对四氯化碳(CCl4)诱导的大鼠慢性肝损伤的作用。用CCl4(0.5 ml/kg,每周两次,腹腔注射6或9周)进行处理,经生化和组织学检查显示,导致了明显的坏死、脂肪变性和纤维化,并且溴磺酞钠(BSP)清除试验显著降低。马洛替酯(50 mg/kg,口服,每周5天,与CCl4同时给药6周)抑制了血浆转氨酶活性的升高,并显著降低了肝脏中脂质和胶原蛋白的积累;组织学证实了马洛替酯的这种保护作用。与中毒对照大鼠相比,马洛替酯治疗的中毒大鼠的BSP清除试验恢复到正常水平,并且肝胶原合成活性的升高有所降低。当给在前6周已经中毒的大鼠给予马洛替酯(100 mg/kg,口服,每周5天)3周时,也发现了相同的效果。马洛替酯能够防止在CCl4中毒的最后3周出现的肝脏病变的加重。这些结果清楚地表明,马洛替酯能够显著减轻大鼠慢性CCl4中毒诱导的肝脏疾病。